

ECAT FOUNDATION

External quality Control for Assays and Tests

With a focus on Thrombosis and Haemostasis

REPORT



SURVEY 2025-L3

Lupus Anticoagulant

Labcode 1492

Date of Issue : 24-October-2025

Survey : 2025-L3

Report : Lupus Anticoagulant

Note:

In the Survey Manual 2025 detailed information is given regarding the ECAT external quality assessment programme, including the statistical evaluation and explanation of the report.

This Survey Manual 2025 should be considered as an integral part of this survey report.

Please notice the information regarding the homogeneity of samples used and the between-laboratory variation in the paragraph on the statistical evaluation of the Survey Manual.

General Information**Exclusion of results**

Results < [value] or > [value] are excluded from the statistical analysis. When other results (e.g., deviating results) are excluded from the statistical analysis, these results are placed between brackets.

Lupus Anticoagulant

When selecting the unit seconds; all results should be reported in seconds and not partly in ratios; e.g., the result for the ECAT sample, the result for normal plasma and the result for MRI.

Antiphospholipid Antibodies

Please be aware of the selection of the correct unit for the method group "IL Acustar / INOVA Quanta Flash". Since there is a difference in the order of magnitude between the results of the "IL Acustar / INOVA Quanta Flash" method group and the other methods, it is expressed in the report as CU/mL instead of U/mL.

Complaints

Any complaints regarding this survey report should be reported to the ECAT before **December 16th, 2025**. Complaints received after this date will not be taken into consideration.

This report is authorized by:

Dr. M.J. van Essen-Hollestelle
Programme Expert

Note: The current Survey Manual can be downloaded from the 'Participant Area' of the ECAT website. Login and select the option 'View Documents'.

ECAT Foundation

Director: Dr. P. Meijer
ECAT Office
P.O. Box 107
2250 AC Voorschoten, The Netherlands
phone +31 (0) 71 3030 910; fax + 31 (0) 71 3030 919
E-mail: info@ecat.nl
Website: www.ecat.nl
VAT number: NL802836872B01

Registration number with the Chamber of Commerce (KvK) Gouda : 41174102
General terms of delivery are applicable to all our services.

All rights reserved. No part of this report may be reproduced, stored in a retrieval system, or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from the ECAT Foundation.
Appendices are an integral part of the total report.

Lupus Anticoagulant
Screening

Sample No 25.186

Sample Details Plasma positive for Lupus Anticoagulant (LA Ratio approx. 1.6)

Prior Use Prior Use: None

Unit Ratio

Expiry Date 31-May-2027

 Homogeneity 0.5 % **Homogeneity Parameter** LA ratio

For any method used for the measurement of this parameter with a **CV ≤ 1.7%** the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants 639

 Number of Responders 591 **Response Rate** 92 %

Assay	Elevated	Not elevated	Borderline	No Classification
APTT	421	3	0	12
dAPTT	14	1	0	0
dPT	7	0	0	0
dRVVT	612	2	0	23
KCT	3	0	0	0
Other	1	0	0	0
PNP	2	0	0	1
PT	6	2	0	0
SCT	157	0	0	9




Assay	Your classification					
	Screening 1			Screening 2		Screening 3
	TS1	TS2	TS3			
APTT	Elevated	Elevated				
dAPTT						
dPT						
dRVVT			Elevated			
KCT						
Other						
PNP						
PT						
SCT						

Ratio Normal Plasma	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	371	2.09	24.8	1.09 - 5.25	1	1.35	-1.43	2.24	0.28		
Hyphen-Biomed Cephen LS	9	3.82		3.03 - 5.07							
Precision Biologic CRYOcheck Hex LA Star	5	1.67		1.41 - 1.76							
Roche aPTT Lupus	5	2.11		1.64 - 4.18							
Siemens Actin FS	7	4.39		3.58 - 4.56							
Siemens Actin FSL	90	2.12	10.0	1.25 - 3.55	1			2.24	0.54		
Siemens Pathromtin SL	19	1.39	14.2	1.09 - 2.09	1	1.35	-0.21				
Stago PTT Automate/STA PTT	12	1.71	5.5	1.51 - 1.94							
Stago PTT LA	89	2.23	12.3	1.47 - 2.94							
Stago Staclot LA	14	1.53	10.4	1.37 - 1.91							
Werfen APTT SP	50	2.89	33.4	1.49 - 5.25							
Werfen HemosIL SynthAsil	42	1.73	6.0	1.34 - 2.07							
Werfen MixCon	14	1.59	8.4	1.15 - 1.78							
dAPTT	13	2.17	16.0	1.09 - 2.75							
Stago PTT LA	8	2.32		2.01 - 2.75							
DRVVT	564	1.90	10.7	1.00 - 3.51	1				1.79	-0.56	
Hyphen Biomed Hemoclot LA-S	6	2.25		2.04 - 2.61							
Precision Biologic LA check	6	1.98		1.75 - 2.40							
Roche Lupus S	10	1.79	3.1	1.66 - 1.98							
Siemens LA1 screen	231	1.91	11.3	1.00 - 2.59	1				1.79	-0.56	
Stago DRVVT screen	76	1.77	10.0	1.35 - 2.29							
Technoclone LA Screen	6	2.12		1.75 - 2.38							
Werfen HemosIL dRVVT screen	220	1.93	9.2	1.13 - 3.51							
PT	7	1.27		1.13 - 1.72							
SCT	155	2.41	20.9	1.29 - 7.13							
Werfen SCT screen	154	2.40	20.8	1.29 - 4.38							

Assays

APTT

DRVVT




Lupus Anticoagulant

Screening


Ratio MRI	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	121	2.06	25.8	1.29 - 4.66	1	1.32	-1.40	2.14	0.15		
Siemens Actin FSL	28	2.04	6.9	1.71 - 2.30	1			2.14	0.69		
Siemens Pathromtin SL	15	1.39	7.2	1.29 - 2.44	1	1.32	-0.71				
Stago PTT Automate/STA PTT	6	1.68		1.58 - 1.86							
Stago PTT LA	21	2.14	14.6	1.65 - 2.94							
Werfen APTT SP	16	3.14	19.7	2.48 - 4.66							
Werfen HemosIL SynthAsil	13	1.72	7.5	1.55 - 1.93							
DRVVT	118	1.90	10.4	1.37 - 3.24	1				2.08	0.92	
Roche Lupus S	6	1.83		1.64 - 2.11							
Siemens LA1 screen	67	1.95	9.5	1.37 - 2.55	1				2.08	0.71	
Stago DRVVT screen	13	1.75	9.7	1.41 - 1.95							
Werfen HemosIL dRVVT screen	28	1.85	8.3	1.57 - 3.24							
PT	6	1.25		1.23 - 1.62							
SCT	16	2.27	19.0	1.68 - 3.22							
Werfen SCT screen	16	2.27	19.0	1.68 - 3.22							

Assays


APTT



DRVVT



DRVVT



Comments

Several participants selected the wrong unit, e.g., ratio while the result was likely to be in seconds. Other participants reported their result for the ECAT plasma in seconds, while the result for their reference plasma or the mean of the reference interval was reported as a ratio or as delta seconds. In all these cases, the ratio between the ECAT plasma and the laboratory's own reference plasma and/or the mean of the reference interval could not be correctly calculated. Therefore all these results were excluded from the statistical analysis.

The vast majority of screening tests performed (99%), were classified as elevated.

In general, comparable results were observed for the ratio ECAT plasma over Normal Plasma and ratio ECAT plasma over Mean Reference Interval (MRI).

Lupus Anticoagulant
Mixing (screening)
Sample No 25.186

Sample Details Plasma positive for Lupus Anticoagulant (LA Ratio approx. 1.6)

Prior Use Prior Use: None

Unit Ratio

Expiry Date 31-May-2027

Homogeneity 0.5 % **Homogeneity Parameter** LA ratio

For any method used for the measurement of this parameter with a **CV** \leq 1.7% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants 639

Number of Responders 426 **Response Rate** 67 %



Assay	Elevated	Not elevated	Borderline	No Classification
APTT	253	39	0	8
dAPTT	10	1	0	1
dPT	2	1	0	0
dRVVT	308	39	0	13
KCT	2	0	0	0
PNP	0	0	0	0
PT	1	2	0	1
SCT	86	4	0	1

Assay	Your classification					
	Mixing 1			Mixing 2		Mixing 3
		TS2	TS3			
APTT		Not elevated				
dAPTT						
dPT						
dRVVT			Elevated			
KCT						
PNP						
PT						
SCT						


Ratio Normal Plasma	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	271	1.41	14.6	0.70 - 4.56	1				1.28	-0.59	
Hyphen-Biomed Cephen LS	10	1.75	5.0	1.56 - 1.91							
Siemens Actin FS	5	1.31		1.12 - 4.56							
Siemens Actin FSL	64	1.31	7.2	1.10 - 2.57	1				1.28	-0.26	
Siemens Pathromtin SL	11	1.29	38.7	0.70 - 2.06							
Stago PTT Automate/STA PTT	13	1.30	8.1	1.21 - 1.87							
Stago PTT LA	81	1.44	9.7	1.14 - 2.27							
Werfen APTT SP	33	1.57	7.2	1.23 - 3.89							
Werfen HemosIL SynthAsil	30	1.28	9.8	1.01 - 1.78							
Werfen MixCon	9	1.57		1.11 - 1.71							
dAPTT	9	1.39		1.32 - 1.65							
Stago PTT LA	8	1.38		1.32 - 1.65							
dRVVT	335	1.35	9.3	0.79 - 3.43	1					1.25	-0.74
Roche Lupus S	7	1.16		0.98 - 1.30							
Siemens LA1 screen	161	1.33	8.3	0.79 - 3.43	1					1.25	-0.68
Stago DRVVT screen	46	1.29	8.0	1.12 - 1.82							
Werfen HemosIL dRVVT screen	108	1.42	9.7	0.98 - 2.00							
SCT	87	1.74	17.2	1.20 - 2.92							
Werfen SCT screen	86	1.74	17.4	1.20 - 2.92							

Assays

APTT




DRVVT



Lupus Anticoagulant
Mixing (screening)

Ratio MRI	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	73	1.36	16.3	1.02 - 2.60	1			1.23	-0.57		
Siemens Actin FSL	21	1.27	6.1	1.14 - 2.60	1			1.23	-0.47		
Siemens Pathromtin SL	9	1.06		1.02 - 2.40							
Stago PTT Automate/STA PTT	5	1.28		1.21 - 1.29							
Stago PTT LA	15	1.39	10.8	1.16 - 1.85							
Werfen APTT SP	10	1.56	8.3	1.36 - 1.70							
Werfen HemosIL SynthAsil	5	1.28		1.16 - 1.50							
DRVVT	74	1.32	8.5	0.97 - 2.26	1					1.46	1.23
Roche Lupus S	6	1.13		0.97 - 1.39							
Siemens LA1 screen	41	1.33	7.4	1.14 - 1.97	1					1.46	1.29
Stago DRVVT screen	8	1.31		1.18 - 1.45							
Werfen HemosIL dRVVT screen	15	1.35	11.7	1.20 - 2.26							
SCT	12	1.64	17.5	1.32 - 2.02							
Werfen SCT screen	12	1.64	17.5	1.32 - 2.02							

Assays
APTT
DRVVT

Comments

Several participants selected the wrong unit, e.g., ratio while the result was likely to be in seconds. Other participants reported their result for the ECAT plasma in seconds, while the result for their reference plasma or the mean of the reference interval was reported as a ratio. In all these cases, the ratio between the ECAT plasma and the laboratory's own reference plasma and/or the mean of the reference interval could not be correctly calculated. Therefore all these results were excluded from the statistical analysis.

The majority of mixing tests performed (89%), were classified as elevated.

In general, comparable results were observed for the ratio ECAT plasma over Normal Plasma and ratio ECAT plasma over Mean Reference Interval (MRI).

Lupus Anticoagulant

Confirmation

Sample No 25.186

Sample Details Plasma positive for Lupus Anticoagulant (LA Ratio approx. 1.6)

Prior Use Prior Use: None

Unit **Ratio**

Expiry Date 31-May-2027

Homogeneity

Homogeneity Parameter

LA ratio

For any method used for the measurement of this parameter with a **CV ≤ 1.7%** the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.




Number of Participants 639

Number of Responders 582 **Response Rate** 91 %

Assay	Elevated	Not elevated	Borderline	No Classification
APTT	159	26	0	26
dAPTT	9	0	0	1
dPT	6	0	0	1
dRVVT	460	108	0	68
Other	1	0	0	0
PNP	6	1	0	3
SCT	131	15	0	20




Ratio Normal Plasma

	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	167	2.51	60.5	0.69 - 5.54							
Hyphen Biomed Cephen	6	2.70		1.77 - 4.88							
Precision Biologic CRYOcheck Hex LA Cor	7	1.21		1.16 - 4.78							
Siemens Actin FS	74	3.80	18.0	1.08 - 5.54							
Stago PTT LA	6	1.92		1.40 - 3.87							
Stago Staclot LA	28	1.22	11.2	0.69 - 1.99							
Werfen Hemosil SynthAFax	17	1.15	4.5	0.87 - 1.70							
Werfen MixCon	14	1.19	7.5	1.07 - 1.58							
dAPTT	8	1.58		1.14 - 6.31							
dPT	5	1.70		1.15 - 3.20							
DRVVT	568	1.27	8.4	0.90 - 2.23	1					1.30	0.30
Hyphen Biomed Hemoclot LA-C	6	1.79		1.67 - 2.04							
Precision Biologic LA sure	5	1.45		1.24 - 2.21							
Roche Lupus C	10	1.35	6.8	1.21 - 1.48							
Siemens LA2 confirmation	233	1.29	7.6	1.00 - 1.64	1					1.30	0.10
Stago DRVVT Confirm	74	1.25	6.3	1.06 - 1.68							
Technoclone LA Confirm	6	1.32		1.21 - 1.48							
Werfen HemosIL dRVVT confirm	227	1.24	8.6	0.90 - 1.95							
PNP	6	1.11		0.46 - 1.40							
SCT	154	1.46	12.8	0.94 - 2.67							
Werfen HemosIL SCT confirm	153	1.46	12.6	0.94 - 2.67							

Assays
APTT

DRVVT


Lupus Anticoagulant
Confirmation

Ratio MRI	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	37	2.91	53.1	1.06 - 5.55							
Siemens Actin FS	21	3.94	17.6	2.28 - 5.55							
Stago Staclot LA	7	1.27		1.11 - 2.31							
dRVVT	114	1.33	10.0	1.01 - 1.92	1					1.60	1.99
Roche Lupus C	5	1.41		1.28 - 1.46							
Siemens LA2 confirmation	66	1.37	10.4	1.09 - 1.71	1					1.60	1.60
Stago DRVVT Confirm	13	1.26	5.4	1.01 - 1.35							
Werfen HemosIL dRVVT confirm	27	1.28	8.6	1.12 - 1.92							
SCT	16	1.44	14.2	1.23 - 2.13							
Werfen HemosIL SCT confirm	16	1.44	14.2	1.23 - 2.13							

Assays

APTT

DRVVT

Comments

Several participants selected the wrong unit, e.g., ratio while the result was likely to be in seconds, or vice versa. Other participants reported their result for the ECAT plasma in seconds, while the result for their reference plasma or the mean of the reference interval was reported as a ratio, or vice versa. In all these cases, the ratio between the ECAT plasma and the laboratoire's own reference plasma and/or the mean of the reference interval could not be correctly calculated. Several participants reported also a confirmation result in Delta Seconds. However the difference in clotting time between the screen and confirmation test (or reagent 1 and reagent 2) should be reported in the interpretation section. All these results were excluded from the statistical analysis.

The majority of confirmation tests performed (84%), were classified as elevated.

In general, comparable results were observed for the ratio ECAT plasma over Normal Plasma and ratio ECAT plasma over Mean Reference Interval (MRI).


Lupus Anticoagulant
Mixing (confirm)

Sample No	25.186						
Sample Details	Plasma positive for Lupus Anticoagulant (LA Ratio approx. 1.6)						
Prior Use	Prior Use: None						
Unit	Ratio						
Expiry Date	31-May-2027						
Homogeneity	0.5 %	Homogeneity Parameter		LA ratio			
		For any method used for the measurement of this parameter with a CV ≤ 1.7% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.					
Number of Participants	639						
Number of Responders	230	Response Rate		36 %			

Assay	Elevated	Not elevated	Borderline	No Classification
APTT	39	33	0	5
dAPTT	7	0	0	1
dPT	0	0	0	0
dRVVT	78	131	0	12
PNP	1	0	0	0
SCT	17	35	0	1



Assay	Your classification								
	Mixing 1			Mixing 2			Mixing 3		
			TS3						
APTT									
dAPTT									
dPT									
dRVVT			Not elevated						
PNP									
SCT									

Ratio Normal Plasma	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	69	1.20	10.4	0.99 - 4.30							
Siemens Actin FS	33	1.14	8.4	0.99 - 1.67							
Werfen Hemosil SynthAFax	5	1.16		1.12 - 1.36							
Werfen MixCon	8	1.15		1.08 - 1.78							
dRVVT	206	1.09	5.2	0.86 - 1.76	1					1.08	-0.23
Siemens LA2 confirmation	108	1.09	4.4	0.88 - 1.56	1					1.08	-0.31
Stago DRVVT Confirm	20	1.10	6.4	1.02 - 1.40							
Werfen Hemosil dRVVT confirm	69	1.09	6.5	0.86 - 1.76							
SCT	50	1.16	9.3	0.96 - 1.94							
Werfen Hemosil SCT confirm	49	1.15	8.8	0.96 - 1.94							

Assays


Lupus Anticoagulant
Mixing (confirm)

Ratio MRI	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	12	1.26	17.1	1.03 - 1.54							
Siemens Actin FS	7	1.10		1.03 - 1.22							
dRVVT	44	1.15	9.8	0.96 - 1.60	1					1.32	1.52
Siemens LA2 confirmation	28	1.17	9.8	1.03 - 1.43	1					1.32	1.34
Werfen HemosIL dRVVT confirm	11	1.14	8.8	1.04 - 1.60							
SCT	7	1.10		1.01 - 1.29							
Werfen HemosIL SCT confirm	7	1.10		1.01 - 1.29							

Assays

DRVVT

Comments

Several participants selected the wrong unit, e.g., ratio while the result was likely to be in seconds, or vice versa. Other participants reported their result for the ECAT plasma in seconds, while the result for their reference plasma or the mean of the reference interval was reported as a ratio or vice versa. In all these cases, the ratio between the ECAT plasma and the laboratory's own reference plasma and/or the mean of the reference interval could not be correctly calculated. All these results were excluded from the statistical analysis.

The majority of mixing confirmation tests performed (58%), were classified as not elevated.

In general, comparable results were observed for the ratio ECAT plasma over Normal Plasma and ratio ECAT plasma over Mean Reference Interval (MRI).

Lupus Anticoagulant


Interpretation

Delta Seconds



	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	83	22.36	55.7	4.00 - 93.80							
Precision Biologic CRYOcheck Hex LA Cor	9	25.20		10.90 - 31.00							
Siemens Actin FS	21	36.76	50.8	4.00 - 59.00							
Stago Staclot LA	37	15.32	32.8	6.00 - 24.40							
dRVVT	124	27.40	22.7	1.55 - 67.10							
Siemens LA2 confirmation	63	27.00	15.2	11.60 - 67.10							
Stago DRVVT Confirm	11	18.90	42.7	1.55 - 36.90							
Werfen HemosIL dRVVT confirm	44	30.59	16.8	11.10 - 61.00							
PNP	5	7.10		3.40 - 15.60							
SCT	26	39.56	37.2	17.90 - 67.00							
Werfen HemosIL SCT confirm	26	39.56	37.2	17.90 - 67.00							

Assays

APTT



DRVVT



Comments

It is not clear whether all results submitted for Delta Seconds reflect in all cases the difference in clotting time between the screen and confirmation test (or reagent 1 and reagent 2).

Please submit for Delta Seconds only the value which is the difference in clotting time between the screen and confirmation test (or difference between reagent 1 and reagent 2).

The following participants reported deviating results which were excluded from the statistical analysis:

803 : 0
1781 : 125
1602 : 260.7

Some participants reported their result for Delta Seconds as a negative result. Please, report in future surveys the result without the negative prefix.

Lupus Anticoagulant

Interpretation


Ratio Screen/Confirmation - Standard

	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	27	1.12	55.2	0.43 - 2.79							
Siemens Actin FS	14	0.69	47.5	0.43 - 1.50							
dRVVT	117	1.55	8.3	1.08 - 1.96	1					1.57	0.12
Siemens LA2 confirmation	81	1.56	6.7	1.18 - 1.96	1					1.57	0.05
Stago DRVVT Confirm	7	1.42		1.26 - 1.56							
Werfen HemosIL dRVVT confirm	19	1.60	9.9	1.08 - 1.84							
SCT	8	1.73		1.33 - 3.92							
Werfen HemosIL SCT confirm	7	1.72		1.33 - 1.93							

Assays

APTT

DRVVT



Comments

Some participants did not indicate which type of ratio screen/confirmation they reported (standard ratio or normalised ratio). These results have been excluded from the statistical analysis. **Don't forget to select the type of ratio in the next survey.**

The average ratio screen / confirmation is in general in line with the expected LA ratio (approx. 1.6). For the assay type "APTT" in combination with the method Siemens Actin FS the LA ratio is slightly lower compared to the other method types.

The following participants reported deviating results which were excluded from the statistical analysis:

271 : 12.6




296A (instr. 1) : 15

296A (instr. 2) : 16.4

66603860 : 13

Lupus Anticoagulant
Interpretation
Ratio Screen/Confirmation - Normalised

	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	101	1.00	48.6	0.41 - 2.40							
Siemens Actin FS	56	0.65	31.8	0.41 - 1.80							
Stago PTT LA	5	1.35		0.60 - 2.40							
Werfen Hemosil SynthAFax	12	1.39	6.6	1.28 - 2.30							
Werfen MixCon	12	1.38	8.4	1.24 - 1.54							
dRVVT	379	1.47	11.1	0.96 - 2.21							
Hyphen Biomed Hemoclot LA-C	7	1.18		1.10 - 1.52							
Roche Lupus C	6	1.33		1.29 - 1.45							
Siemens LA2 confirmation	129	1.46	9.9	1.00 - 1.74							
Stago DRVVT Confirm	54	1.39	9.5	1.17 - 1.95							
Werfen HemosIL dRVVT confirm	175	1.53	10.3	1.13 - 2.21							
SCT	129	1.63	17.7	1.06 - 2.22							
Werfen HemosIL SCT confirm	129	1.63	17.7	1.06 - 2.22							

Assays
APTT
DRVVT

Comments

Some participants did not indicate which type of ratio screen/confirmation they reported (standard ratio or normalised ratio). These results have been excluded from the statistical analysis. **Don't forget to select the type of ratio in the next survey.**

The average ratio screen / confirmation is in general in line with the expected LA ratio (approx. 1.6). For the assay type "APTT" in combination with the method Siemens Actin FS the LA ratio is slightly lower compared to the other method types, as also was observed for the parameter: "Ratio Screen/Confirmation - Standard".

Most participants reported their ratio screen / confirmation as normalised ratio.



The following participant reported a deviating result which was excluded from the statistical analysis:

9907349 :

25

Lupus Anticoagulant
Interpretation
Percentage Correction - Standard

	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	12	43.83	64.3	5.30 - 95.00							
Siemens Actin FS	5	70.72		5.30 - 95.00							
dRVVT	54	36.38	18.6	1.72 - 64.10							
Siemens LA2 confirmation	36	35.71	11.2	14.70 - 64.10							
Stago DRVVT Confirm	5	31.40		20.62 - 36.56							
Werfen HemosIL dRVVT confirm	9	44.70		1.72 - 48.00							
SCT	9	45.20		23.90 - 74.50							
Werfen HemosIL SCT confirm	8	44.10		23.90 - 55.37							

Assays

DRVVT

Comments

Some participants did not indicate which type of correction they have reported (standard correction or normalised correction). These results have been excluded from the statistical analysis. Don't forget to select the type of correction in the next survey.



The following participant reported a deviating result which was excluded from the statistical analysis:

9907615 : 0%

Some participants reported their result for percentage correction as a negative result. Please, report in future surveys the result without the negative prefix.

Lupus Anticoagulant
Interpretation
Percentage Correction - Normalised

	n	assigned value	CV (%)	Range	Test System	Panel 1	Z-score	Panel 2	Z-score	Panel 3	Z-score
APTT	22	46.50	46.0	1.00 - 91.24							
Siemens Actin FS	7	65.00		40.00 - 91.24							
dRVVT	77	33.15	22.4	1.00 - 92.00							
Siemens LA2 confirmation	32	34.74	16.9	16.00 - 78.20							
Stago DRVVT Confirm	10	29.97	18.7	20.60 - 40.56							
Werfen HemosIL dRVVT confirm	33	33.38	26.2	1.00 - 92.00							
SCT	27	34.17	40.6	1.00 - 65.90							
Werfen HemosIL SCT confirm	27	34.17	40.6	1.00 - 65.90							

Assays

DRVVT

Comments

Some participants did not indicate which type of correction they have reported (standard correction or normalised correction). These results have been excluded from the statistical analysis. Don't forget to select the type of correction in the next survey.

Some participants reported their result for percentage correction as a negative result. Please, report in future surveys the result without the negative prefix.

Lupus Anticoagulant
Final Conclusion

Testing Strategies	Classification				Your Classification			
	Equivocal	LA detected	LA not detected	No conclusion	Test System	Panel 1	Panel 2	Panel 3
Screen test only	2	15	1	11	1			
					2			
					3			
Screen and mixing test	4	60	9	9	1			
					2			
					3			
Screen and confirm test	15	423	31	15	1			
					2			
					3			
Screen, mixing and confirm test		240	35	9	1			LA detected
					2			
					3			
Screen, confirm, mixing test	3	144	20	5	1			
					2			
					3			
Mixing - confirmation	1	32	1	3	1			
					2			
					3			

Final Conclusion				Your Results		
Counts				Test System 1	Test System 2	Test System 3
LA detected	LA not detected	Equivocal	No Conclusion			
446	27	23	17	LA detected		

Comments

The sample used in this survey was plasma from a patient diagnosed with Lupus Anticoagulant (LA Ratio = approx. 1.6). No other types of inhibitors were present.

In total 496 participants gave a final conclusion. Of the participants who gave a final conclusion, approximately 90% classified the sample as positive. Less than five percent classified the sample as equivocal. Thus, the vast majority of the participants correctly classified this sample as positive. A minority (3.4%) of the participants classified this sample as negative, this does not seem to be affected by the test strategy but is probably caused by the sensitivity of the reagent and the local interpretation of the result (e.g., local cut-off value used).

Participants stated that there is an indication that this sample is weakly positive for lupus anticoagulant but in real clinical practice this should be confirmed in a new sample after 12 weeks.

Some participants indicated that the presence of heparin and/or factor deficiency should be excluded. Another participant indicated that pretreatment with DOAC STOP left the parameters unchanged and concluded that there was no indication for the presence of DOAC in the sample.

Lupus Anticoagulant
AntiCardiolipin Antibodies IgG


Sample No	25.186
Sample Details	Plasma positive for Lupus Anticoagulant (LA Ratio approx. 1.6)
Prior Use	Prior Use: None
Unit	GPL, U/mL, µg/mL, CU/mL
Expiry Date	31-May-2027
Homogeneity	0.5 % Homogeneity Parameter LA ratio For any method used for the measurement of this parameter with a CV \leq 1.7% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants	639
Number of Responders	238

Response Rate 37 %

Classification	Negative	Borderline	Low Positive	Medium Positive	High Positive	No Conclusion
Total	237	1	1	0	0	1

IgG	n	assigned value	CV (%)	range	Test System 1 Result	z-score	Test System 2 Result	z-score	Test System 3 Result	z-score
U/mL, µg/mL, GPL/MPL	131	2.0	54.8	0.0 - 12.0						
Aeskulisa Diagnostic GmbH	6	3.7		2.0 - 6.0						
Euroimmun	13	4.1	36.7	2.6 - 6.2						
Orgentec (Alegria)	16	1.0	24.2	0.7 - 1.8						
Orgentec (Elisa)	11	0.9	36.5	0.5 - 1.3						
Thermo Scientific EliA	71	2.0	34.5	0.9 - 5.2						
CU/mL	63	3.2	16.2	0.8 - 16.2						
Werfen Acustar / INOVA Quanta Flash	63	3.2	16.2	0.8 - 16.2						

GPL, U/mL, µg/mL

Comments

Most of the participants reported a negative classification.

The following participants reported deviating results which were excluded from the statistical analysis:

737 : 0 CU/mL
 1353 : 0.19 U/mL
 9907155: 0 U/mL

Lupus Anticoagulant
AntiCardiolipin Antibodies IgM


Sample No	25.186
Sample Details	Plasma positive for Lupus Anticoagulant (LA Ratio approx. 1.6)
Prior Use	Prior Use: None
Unit	MPL, U/mL, µg/mL, CU/mL
Expiry Date	31-May-2027
Homogeneity	0.5 % Homogeneity Parameter LA ratio For any method used for the measurement of this parameter with a CV \leq 1.7% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants	639
Number of Responders	230

Response Rate 36 %

Classification	Negative	Borderline	Low Positive	Medium Positive	High Positive	No Conclusion
Total	230	1	0	0	0	1

IgG	n	assigned value	CV (%)	range	Test System 1 Result	z-score	Test System 2 Result	z-score	Test System 3 Result	z-score
U/mL, µg/mL, GPL/MPL	113	1.9	51.4	0.5 - 8.0						
Aeskulisa Diagnostic GmbH	5	1.0		0.6 - 5.1						
Euroimmun	7	2.0		2.0 - 2.3						
Orgentec (Alegria)	16	0.8	23.8	0.6 - 1.8						
Orgentec (Elisa)	10	1.1	46.6	0.5 - 1.8						
Thermo Scientific EliA	61	2.3	37.1	1.0 - 4.6						
CU/mL	83	2.7	13.0	1.7 - 3.4						
Werfen Acustar / INOVA Quanta Flash	83	2.7	13.0	1.7 - 3.4						

MPL, U/mL, µg/mL

Comments

Most of the participants reported a negative classification.

The following participants reported deviating results which were excluded from the statistical analysis:

1353 : 0.16 U/mL

9065 : 0 U/mL

9907155: 0 U/mL

Lupus Anticoagulant
β2-Glycoprotein I Antibodies IgG

Sample No 25.186

Sample Details Plasma positive for Lupus Anticoagulant (LA Ratio approx. 1.6)

Prior Use Prior Use: None

Unit U, U/mL, µg/mL, CU/mL

Expiry Date 31-May-2027

Homogeneity 0.5 %

Homogeneity Parameter

LA ratio

For any method used for the measurement of this parameter with a **CV** \leq 1.7% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants 639


Number of Responders 231

Response Rate

36 %

Classification	Negative	Borderline	Low Positive	Medium Positive	High Positive	No Conclusion
Total	233	0	0	0	0	1

IgG	n	assigned value	CV (%)	range	Test System 1 Result	z-score	Test System 2 Result	z-score	Test System 3 Result	z-score
U, U/mL, µg/mL	110	1.3	37.0	0.0 - 7.8	0.6	-1.47				
Aeskulisa Diagnostic GmbH	6	2.3		1.0 - 3.0						
Euroimmun	5	2.0		2.0 - 7.8						
Orgentec (Alegria)	16	1.0	21.0	0.7 - 1.4						
Orgentec (Elisa)	12	0.9	63.0	0.2 - 1.8	0.6	-0.57				
Thermo Scientific EliA	61	1.3	25.6	0.5 - 2.3						
CU/mL	30	5.3	36.9	0.9 - 10.0						
Werfen Acustar / INOVA Quanta Flash	30	5.3	36.9	0.9 - 10.0						

U, U/mL, µg/mL

Comments

Most of the participants reported a negative classification.

The following participants reported deviating results which were excluded from the statistical analysis:

737 : 0 CU/mL

9065 : 0 U/mL

9907155: 0 U/mL

Lupus Anticoagulant
β2-Glycoprotein I Antibodies IgM


Sample No	25.186
Sample Details	Plasma positive for Lupus Anticoagulant (LA Ratio approx. 1.6)
Prior Use	Prior Use: None
Unit	U, U/mL, µg/mL, CU/mL
Expiry Date	31-May-2027
Homogeneity	0.5 % Homogeneity Parameter LA ratio For any method used for the measurement of this parameter with a CV \leq 1.7% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants	639
Number of Responders	218

Response Rate 34 %

Classification	Negative	Borderline	Low Positive	Medium Positive	High Positive	No Conclusion
Total	219	0	1	0	0	1

IgG	n	assigned value	CV (%)	range	Test System 1 Result	z-score	Test System 2 Result	z-score	Test System 3 Result	z-score
U, U/mL, µg/mL	79	1.6	73.6	0.1 - 10.1	0.9	-0.61				
Aeskulisa Diagnostic GmbH	6	2.2		1.0 - 4.0						
Euroimmun	12	4.8	43.9	2.4 - 10.1						
Orgentec (Alegria)	17	0.7	24.4	0.6 - 1.2						
Orgentec (Elisa)	12	1.0	61.6	0.5 - 8.1	0.9	-0.15				
Thermo Scientific EliA	20	1.6	54.9	0.3 - 2.9						
CU/mL	61	1.3	15.3	0.7 - 2.4						
Werfen Acustar / INOVA Quanta Flash	61	1.3	15.3	0.7 - 2.4						

U, U/mL, µg/mL

Comments

Most of the participants reported a negative classification.

The following participants reported deviating results which were excluded from the statistical analysis:

737 : 0 CU/mL

9907155 : 0 U/mL